The optimal number of induction chemotherapy cycles in clinically lymph node‐positive bladder cancer

Markus von Deimling(Universität Hamburg), Laura S. Mertens(Oncode Institute), David D‘Andrea(Medical University of Vienna), Andrea Gallioli(Puigvert Foundation), Philippe E. Spiess(Moffitt Cancer Center), Keiichiro Mori(Jikei University School of Medicine), Benjamin Pradère, Yair Lotan(Southwestern Medical Center), Karl H. Tully(Universitätsklinik Marien Hospital Herne), Felice Crocetto(University of Naples Federico II), Andrea Minervini(Azienda Ospedaliero-Universitaria Careggi), Peter C. Black(University of British Columbia), Abhinav Khanna(Mayo Clinic in Arizona), Roger Li(Unknown), Simone Albisinni(University of Rome Tor Vergata), Gautier Marcq(Centre National de la Recherche Scientifique), Michael Rink(Marienkrankenhaus Hamburg), Jacob Taylor(The University of Texas Southwestern Medical Center), Moritz Maas(University of British Columbia), Ekaterina Laukhtina(Sechenov University), Renate Pichler(Innsbruck Medical University), Bernhard Kiss(University of Bern), Shahrokh F. Shariat(Universitätszahnklinik Wien), Maud Velev(Université Paris-Saclay), Marco Moschini(Vita-Salute San Raffaele University), Guus A. H. Tendijck(The Netherlands Cancer Institute), Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Francesco Del Giudice(Sapienza University of Rome), Marc A. Furrer(The Royal Melbourne Hospital), Margit Fisch(Universität Hamburg)
British Journal of Urology
March 12, 2024
Cited by 7


Related Papers